WINT - WINDTREE THERAPEUTICS INC /DE/

1.3
0.100   7.692%

Share volume: 871,895
Last Updated: 04-08-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.07%

PREVIOUS CLOSE
CHG
CHG%
$1.20
0.10
0.08%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
9%
Profitability 0%
Dept financing 17%
Liquidity 20%
Performance 12%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
-28.37%
3 Months
409.40%
6 Months
73.33%
1 Year
-80.53%
2 Year
-72.57%
Key data
Stock price
$1.30
P/E Ratio 
0.00
DAY RANGE
$1.15 - $1.45
EPS 
$0.44
52 WEEK RANGE
$0.09 - $14.75
52 WEEK CHANGE
-$80.99
MARKET CAP 
1.415 M
YIELD 
N/A
SHARES OUTSTANDING 
591.909 K
DIVIDEND
$0.00
EX-DIVIDEND DATE
02-21-2025
NEXT EARNINGS DATE
04-15-2025
BETA 
1.51
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$598,472
AVERAGE 30 VOLUME 
$7,138,412
Company detail
CEO: Craig E. Fraser
Region: US
Website: windtreetx.com
Employees: 30
IPO year: 2016
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Windtree Therapeutics, Inc. focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trials for heart failure, and AEROSURF, an aerosolized KL4 surfactant.

Recent news
loading